CHMP issues positive opinions for Aclasta and Velcade
This article was originally published in Scrip
Novartis's Aclasta (zoledronic acid) and Janssen-Cilag's Velcade (bortezomib) have both received positive opinions from the EU's CHMP relating to extensions of their indications. The committee adopted a negative opinion, however, on extending the indications of Aventis Pharma's docetaxel products Taxotere and Docetaxel Winthrop.
You may also be interested in...
Amgen's investigational bone loss treatment denosumab more than halves osteoporosis patients' risk of new vertebral fractures, new data from a pivotal Phase III trial show.
Gilead Scienceswill need to conduct another clinical trial of its investigational cystic fibrosis treatment aztreonam lysine for inhalation before the drug can be approved, the US FDAhas said.